• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • NORTH AMERICA EDITION
      Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • NORTH AMERICA EDITION
      North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Pharmaceutical Market
    Pharmaceutical News
    Pharmaceutical Stocks
    • Pharmaceutical Market
    • Pharmaceutical News
    • Pharmaceutical Stocks
    pharmaceutical investing

    Theratechnologies Submits Novel Single-Vial Formulation of EGRIFTA (Tesamorelin for Injection) for FDA Approval

    Gabrielle Lakusta
    Jul. 04, 2018 08:30AM PST
    Pharmaceutical Investing

    Theratechnologies (TSX:TH) today announced that it has filed a supplemental new drug application (sNDA) with the Food and Drug Administration (FDA) for a single-vial formulation of EGRIFTA. As quoted in the press release: The filing is based on bioequivalence studies which were completed earlier this year. The new single-vial formulation, known as “F4”, is four times …

    Theratechnologies (TSX:TH) today announced that it has filed a supplemental new drug application (sNDA) with the Food and Drug Administration (FDA) for a single-vial formulation of EGRIFTA.

    As quoted in the press release:

    The filing is based on bioequivalence studies which were completed earlier this year. The new single-vial formulation, known as “F4”, is four times more concentrated than the currently commercialized formulation of EGRIFTA®. The F4 significantly reduces the volume of administration and handling is more user-friendly as it comes in a single vial instead of two. Furthermore, the F4 is stable at room temperature which represents an advantage as EGRIFTA® now requires a cold-chain distribution network from the manufacture to the patient.

    “Given its advantageous and convenient administration profile, the F4 could certainly be well received by patients and physicians. EGRIFTA® remains an important product for Theratechnologies and we are pleased by the perspective of making improvements to this unique and important treatment at this time in its lifecycle,” said Luc Tanguay, President and Chief Executive Officer, Theratechnologies Inc.

    Click here to read the full press release.

    pharmaceutical investingtsx:th
    The Conversation (0)

    Go Deeper

    AI Powered
    Senior woman doing exercises alongside closeup of DNA.

    5 US Longevity and Anti-aging Stocks to Watch in 2025

    Medical pills branded with Canadian flag.

    Canadian Pharma Stocks: 5 Biggest Companies

    Latest News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Pharmaceutical Investing Stocks

    Cardiol Therapeutics

    CRDL:CA
    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×